Company Filing History:
Years Active: 2006
Title: Kerstin Matzku: Innovator in Tumor Treatment
Introduction
Kerstin Matzku is a notable legal representative and inventor based in Zwingenberg, Germany. She has made significant contributions to the field of medical treatment, particularly in the area of tumor therapy. Her innovative approach combines advanced methodologies to enhance the effectiveness of cancer treatments.
Latest Patents
Kerstin Matzku holds a patent for a method of treating tumors, which includes sequential steps for administering a specific antiangiogenic cyclo-arginine-glycine-aspartic acid-containing pentapeptide (cRGD pentapeptide) and a radioimmunotherapeutic agent (RIT). This method targets various types of tumors, including prostate tumors, breast tumors, and non-Hodgkin's lymphoma. The patent outlines a detailed process that aims to improve patient outcomes through a combination of these therapeutic agents.
Career Highlights
Throughout her career, Kerstin has worked with prestigious organizations, including the University of California and Merck Patent GmbH. Her experience in these institutions has allowed her to develop and refine her innovative approaches to cancer treatment.
Collaborations
Kerstin has collaborated with esteemed colleagues such as Sally Joan Denardo and Patricia A Burke. These partnerships have contributed to her research and development efforts in the medical field.
Conclusion
Kerstin Matzku's work in tumor treatment exemplifies the intersection of innovation and medical science. Her contributions continue to pave the way for advancements in cancer therapy.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.